Microvascular invasion is an independent prognostic factor in patients with prostate cancer treated with radical prostatectomy

International Braz J Urol

Volumn 32, Issue 6, 2006, Pages 668-675

  Antunes, Alberto A ^a   Srougi, Miguel ^a,b   Dall'Oglio, Marcos F ^a   Crippa, Alexandre ^a   Paranhos, Mario ^a   Cury, Jose ^a   Nesrallah, Luciano J ^a   Leite, Katia R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Disease progression; Prostate; Prostatectomy; Prostatic neoplasms; Survival analysis

Indexed keywords

ADULT; ARTICLE; CANCER INVASION; CANCER LOCALIZATION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FOLLOW UP; GLEASON SCORE; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; STATISTICAL ANALYSIS;

EID: 33846455821     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/s1677-55382006000600007     Document Type: Article

References (15)

1. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002; 167: 528-34.
2. Mazzucchelli R, Santinelli A, Lopez-Beltran A, Scarpelli M, Montironi R: Evaluation of prognostic factors in radical prostatectomy specimens with cancer. Urol Int. 2002; 68: 209-15.
3. Henson DE, Hutter RV, Farrow G: Practice protocol for the examination of specimens removed from patients with carcinoma of the prostate gland. A publication of the cancer committee, college of American pathologists. Task Force on the Examination of Specimens Removed From Patients With Prostate Cancer. Arch Pathol Lab Med. 1994; 118: 779-83.
4. Bahnson RR, Dresner SM, Gooding W, Becich MJ: Incidence and prognostic significance of lymphatic and vascular invasion in radical prostatectomy specimens. Prostate. 1989; 15: 149-55.
5. Salomao DR, Graham SD, Bostwick DG: Microvascular invasion in prostate cancer correlates with pathologic stage. Arch Pathol Lab Med. 1995; 119: 1050-4.
6. McNeal JE, Yemoto CE: Significance of demonstrable vascular space invasion for the progression of prostatic adenocarcinoma. Am J Surg Pathol. 1996; 20: 1351-60.
7. van den Ouden D, Kranse R, Hop WC, van der Kwast TH, Schroder FH: Microvascular invasion in prostate cancer: prognostic significance in patients treated by radical prostatectomy for clinically localized carcinoma. Urol Int. 1998; 60: 17-24.
8. Herman CM, Wilcox GE, Kattan MW, Scardino PT, Wheeler TM: Lymphovascular invasion as a predictor of disease progression in prostate cancer. Am J Surg Pathol. 2000; 24: 859-63.
9. de la Taille A, Rubin MA, Buttyan R, Olsson CA, Bagiella E, Burchardt M, et al.: Is microvascular invasion on radical prostatectomy specimens a useful predictor of PSA recurrence for prostate cancer patients? Eur Urol. 2000; 38: 79-84.
10. Shariat SF, Khoddami SM, Saboorian H, Koeneman KS, Sagalowsky AI, Cadeddu JA, et al.: Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy. J Urol. 2004; 171: 1122-7.
11. Ito K, Nakashima J, Mukai M, Asakura H, Ohigashi T, Saito S, et al.: Prognostic implication of microvascular invasion in biochemical failure in patients treated with radical prostatectomy. Urol Int. 2003; 70: 297-302.
12. Beahrs OH, Henson DE, Hutter RVP: AJCC Manual for Staging of Cancer, 4th (ed.), Philadelphia, JB Lippincott. 1992.
13. Gleason DF: Histologic Grading and Clinical Staging of Prostatic Carcinoma. In: Tannenbaum M (ed.), Urologic Pathology: The Prostate. Philadelphia, Lea & Febiger. 1977; pp. 171-97
14. Bostwick DG, Foster CS: Examination if radical prostatectomy specimens: Therapeutic and prognostic significance. In: Foster W, Bostwick D (ed.), Pathology of Prostate, Series Major Problems in Pathology. Philadelphia, WB Saunders Co. 1998; vol. 34, p. 172.
15. Ferrari MK, McNeal JE, Malhotra SM, Brooks JD: Vascular invasion predicts recurrence after radical prostatectomy: stratification of risk based on pathologic variables. Urology. 2004; 64: 749-53.